The evidence that in breast carcinoma the activity of AKT was repressed during MET suggests a relationship between AKT inhibition and MET55; (4) c-myc is an important transcription factor overexpressed in aggressive TNBC where its deregulation contributes to disease progression, metastatic potential, and therapeutic resistance56,57. The gene discussed is MYC; the disease is breast carcinoma.